Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study |
| |
| Authors: | J T Thigpen J A Blessing H D Homesley J S Berek W T Creasman |
| |
| Affiliation: | 1. Department of Medicine and Obstetrics and Gynecology, University of Mississippi School of Medicine, Jackson, Mississippi, USA;2. Gynecologic Oncology Group, Cancer Research Scientist V, Roswell Park Memorial Institute, Buffalo, New York, USA;3. Department of Obstetrics and Gynecology, Section on Gynecologic Oncology, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina, USA;4. Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California at Los Angeles School of Medicine, Los Angeles, California, USA;1. Faculty of Applied Sciences, Universiti Teknologi MARA, 40450 Shah Alam, Selangor, Malaysia;2. Faculty of Pharmacy, Universiti Teknologi MARA (UiTM), 42300 Bandar Puncak Alam, Selangor, Malaysia;3. Collaborative Drug Discovery Research (CDDR) Group, Pharmaceutical and Life Sciences Community of Research, Universiti Teknologi MARA (UiTM), 40450 Shah Alam, Selangor, Malaysia;4. Faculty of Science and Technology, Universiti Sains Islam Malaysia, Bandar Baru Nilai, 71800 Nilai, Negeri Sembilan, Malaysia;5. Atta-ur-Rahman Institute for Natural Product Discovery (AuRIns), UiTM Puncak Alam, Selangor, Malaysia;1. Division of Inorganic Chemistry, Department of Chemistry, Aligarh Muslim University, Aligarh 202002, India;2. Department of Ophthalmology, Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, United States;1. Department of Medical Oncology, Medical School, University of Ioannina, Stavros Niarchos Avenue, 45500, Ioannina, Greece;2. Gynaecology Unit, General Hospital “G. Hatzikosta”, Makrigianni Avenue, 45001, Ioannina, Greece;1. Department of Medical Oncology, Lilavati Hospital and Research Centre, Mumbai, India;2. Department of Medical Oncology, Bombay Hospital Institute of Medical Sciences, Mumbai, India;3. Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain;4. Department of Medical Oncology, HCG Hospital and St. Johns Medical College, Bengaluru, India;5. Department of Life Science and Public Health, Catholic University of Sacred Heart, Largo Agostino Gemelli, Rome;6. Department of Women and Child Health, Division of Gynaecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy;7. Department of Medical Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India;8. Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;9. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Dr. Cipto Mangunkusumo General Hospital/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia;10. Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan;11. Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea;12. Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia;13. Division of Medical Oncology, Department of Internal Medicine, University of the Philippines, Philippine General Hospital, Manila, The Philippines;14. Department of Gynaecologic Oncology, KK Women’s and Children’s Hospital, Singapore, Singapore;15. Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan;16. Medical Oncology Unit, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;17. Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand;18. Obstetrics and Gynecology Center, Medpark Hospital, Bangkok, Thailand;19. Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan;20. Division of Medical Oncology, National Cancer Centre, Singapore, Singapore;21. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, U.P. College of Medicine and Philippine General Hospital, Manila, The Philippines;22. Oncology and Radiotherapy Department, KPJ Johor Specialist Hospital, Johor Bahru, Malaysia;23. Department of Hematology and Oncology, CHA Bundang Medical Center (CBMC), CHA University, Seongnam, Gyeonggi-do, Republic of Korea;24. Department of Gynecology and Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan;25. Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China;26. European Institute of Oncology, IRCCS, Milano, Italy;27. Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy;28. Department of Gynecologic Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India;29. Department of Radiation Oncology, Homi Bhabha Cancer Hospital and Research Hospital, Vishakhapatnam, India;30. Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, India;31. Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland;32. Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan;33. ESMO, Lugano, Switzerland |
| |
| Abstract: | Twenty-six patients with advanced or recurrent cancer of the vagina no longer amenable to control with surgery and/or radiotherapy were entered into a phase II study of cisplatin 50 mg/m2 intravenously every 3 weeks. Two were deemed ineligible because of a primary site of origin other than vagina. Two were deemed inevaluable, one because of the lack of measurable disease and the other because she never received drug. The remaining 22 included a variety of histologies (16 squamous cell carcinomas, 2 adenosquamous carcinomas, 1 clear cell carcinoma, 1 leiomyosarcoma, and 2 carcinomas not otherwise specified). One complete responder was observed among the 16 patients with squamous cell carcinoma. Adverse effects were tolerable and were essentially those reported in other series. These results suggest that cisplatin has insignificant activity in advanced or recurrent squamous cell carcinoma of the vagina at least at the dose and schedule tested. No comment can be made regarding the activity of cisplatin in other histologies. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
